Yanling WangDirector of Protein Expression & CLD at Hengenix Biotech, Inc.
I have been working at Hengenix Biotech Inc, a therapeutical Ab developing company, for 11 years focusing on stable cell line development for manufacture and protein expression for early stage lead discovery and function validation. We have established the expression system from random integration to site specific integration, from UCOE to GS, then GS-transposon system. The project involved monoclonal antibody, VHH nanobody, bi-specific, and asymmetrical Abs. Also include the biosimilar and innovated molecules.
Hard-to-express and problematic multi-specific Ab, CLD, development and process, 14:30View Session